Fresenius SE KGaA Valuation
Is 000332902 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 000332902 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 000332902 (CHF53.06) is trading below our estimate of fair value (CHF146.43)
Significantly Below Fair Value: 000332902 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 000332902?
Key metric: As 000332902 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 000332902's PS Ratio? | |
|---|---|
| PS Ratio | 0.8x |
| Sales | €22.81b |
| Market Cap | €18.49b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.4x |
| Enterprise Value/EBITDA | 14.7x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 000332902's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 4.4x | ||
STMN Straumann Holding | 6.9x | 8.6% | CHF 17.6b |
SOON Sonova Holding | 5.2x | 6.3% | CHF 18.9b |
GALE Galenica | 1x | 4.2% | CHF 3.8b |
ALC Alcon | 4.4x | 6.2% | CHF 37.8b |
000332902 Fresenius SE KGaA | 0.8x | 3.6% | CHF 18.8b |
Price-To-Sales vs Peers: 000332902 is good value based on its Price-To-Sales Ratio (0.8x) compared to the peer average (4.4x).
Price to Sales Ratio vs Industry
How does 000332902's PS Ratio compare vs other companies in the European Healthcare Industry?
| 7 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 7 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: 000332902 is expensive based on its Price-To-Sales Ratio (0.8x) compared to the European Healthcare industry average (0.6x).
Price to Sales Ratio vs Fair Ratio
What is 000332902's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.8x |
| Fair PS Ratio | 1.7x |
Price-To-Sales vs Fair Ratio: 000332902 is good value based on its Price-To-Sales Ratio (0.8x) compared to the estimated Fair Price-To-Sales Ratio (1.7x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
COLTENE Holding
CHF 305.9m
Develops, manufactures, and sells disposables, tools, and equipment for dentists and dental laboratories in Europe, the Middle East, Africa, North America, Latin America, and Asia/Oceania.
CLTN
CHF 51.20
7D
-6.2%
1Y
-23.6%
Becton Dickinson
US$66.7b
Develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide.
912061
US$238.02
7D
0%
1Y
-2.2%
Galenica
CHF 3.8b
Operates as a healthcare service provider in Switzerland and internationally.
GALE
CHF 76.30
7D
-0.5%
1Y
8.2%